Late on Friday, Pfizer Inc., the New York City-based American multinational pharmaceutical giant and biotech firm, had lodged an application to US health authorities for an emergency use of its pandemic vaccine that claimed to have achieved a 95 per cent efficacy to successfully prevent the pandemic pathogen in a late-stage human trial, marking up a first such breakthrough move aimed at rigging out a much-required protection against the pandemic contagion.
Nevertheless, Pfizer Inc. had told in a statement earlier in the day that it was going to file an application with US FDA (Food and Drug Administration) for emergency use of its pandemic vaccine, which was developed in collaboration with its German partner BioNTech SE, while followed by the application late on Friday, Pfizer Inc.
shares climbed 1.3 per cent and the US-listed BioNTech shares jumped as much as 9.3 per cent in post-market trading. On top of that, the application to US FDA for an emergency use of Pfizer Inc.’s pandemic vaccine came forth a couple of days after the US pharmaceutical industry behemoth had told in a statement that its final trial results had revealed a 95 per cent efficacy to block out the pandemic pathogen, up from an earlier 90 per cent, while Pfizer Inc.
had also added that its pandemic vaccine trial had not shown any kind of major safety issues.
Pfizer Inc. files for pandemic vaccine authorization
Besides, latest landmark moves from Pfizer Inc. came forth as the US head of pandemic control and supervision, Dr.
Anthony Fauci, was quoted saying in an interview with BBC News earlier this week that one or two potential pandemic vaccines could be authorized in weeks. Meanwhile, as Pfizer Inc.
Chief Executive Alberta Bourla had confirmed the application by posting a video in the company’s official website, US Health and Human Service Secretary Alex Azar said in an interview with CBS, “If the data is solid, we literally could be weeks away from the authorization of a 95% effective vaccine. ”